Letter

Post-marketing surveillance should include effects during pregnancy

BMJ 2005; 330 doi: 10.1136/bmj.330.7486.308-a (Published 3 February 2005)
Cite this as: BMJ 2005;330:308.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Patricia Yeargin, associate medical editor, health promotions (yeargin2000@yahoo.com)
  1. American Cancer Society, 1599 Clifton Road, NE, Atlanta, GA 30329

    EDITOR—I agree that post-marketing surveillance of drugs is desperately needed.1 I further believe that, since information about drugs' effects during human gestation is never studied during pre-marketing, some post-marketing study of fetal effects during pregnancy should be considered.

    I have seen many women's medical care neglected during pregnancy owing to fear of harming the fetus, even when there is no real evidence …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular